Search results for "Prostate cancer"
Points to consider in palliative care
An integrated model of curative and palliative care may lead some physicians to reconsider their role in care at the end of life.
https://immattersacp.org/archives/2018/07/points-to-consider-in-palliative-care.htm
1 Jul 2018
Task Force draft recommendation leaves PSA screening choice up to patients
Clinicians should talk to men ages 55 to 69 about the potential benefits and harms of screening, according to the U.S. Preventive Services Task Force. For men ages 70 years and older, the potential benefits of prostate-specific antigen (PSA)-based screening do not outweigh the harms, the Task Force said.
https://immattersacp.org/weekly/archives/2017/04/18/1.htm
18 Apr 2017
Recalls expanded on defibrillators, infusion pumps
Recalls, warnings, approvals and other regulatory news.
https://immattersacp.org/archives/2010/07/fda.htm
1 Jul 2010
Discussion of stopping cancer screening may go best when focused on lack of benefit instead of limited life expectancy
Survey respondents' most preferred phrase was “your other health issues should take priority”; the least preferred choice was “the doctor does not give an explanation.”
https://immattersacp.org/weekly/archives/2018/07/03/4.htm
3 Jul 2018
FDA approves generic hypertension drugs, looks at Stalevo
Recalls, warnings, approvals and other regulatory news.
https://immattersacp.org/archives/2010/06/fda.htm
1 Jun 2010
Dealing with dementia, Q&As on COVID-19
This issue also covers testosterone and men's health, as well as preconception care.
https://immattersacp.org/archives/2020/05/dealing-with-dementia-qandas-on-covid-19.htm
1 May 2020
High-value management of patients with GI symptoms
Gastroesophageal reflux disease, rectal bleeding, and chronic diarrhea can be controlled better by applying high-value care.
https://immattersacp.org/archives/2017/06/gastro.htm
1 Jun 2017
Clarification to a previous issue
In last week's ACP InternistWeekly, the first sentence of the item on reimbursement cuts and prostate drugs should have read “Medicare reimbursement cuts were associated with reduced use of androgen-deprivation therapy for prostate cancer, particularly among men for whom the benefits of such therapy were unclear.” The item has been updated.
https://immattersacp.org/weekly/archives/2010/11/16/8.htm
16 Nov 2010
Androgen-deprivation therapy associated with increased risk of cardiac mortality in men with cardiovascular problems
Androgen-deprivation therapy (ADT) for prostate cancer was associated with a 5% absolute excess risk of cardiac-specific mortality at 5 years in men with congestive heart failure or prior myocardial infarction, a study found.
https://immattersacp.org/weekly/archives/2014/11/04/6.htm
4 Nov 2014
Warnings on prostate drugs, HIV combination therapy
Recalls, warnings, and approvals.
https://immattersacp.org/archives/2011/01/fda.htm
1 Jan 2011